Infrared (810-nm) low-level laser therapy on rat experimental knee inflammation

Rodney Capp Pallotta, Jan Magnus Bjordal, Lúcio Frigo, Ernesto Cesar Pinto Leal Junior, Simone Teixeira, Rodrigo Labat Marcos, Luciano Ramos, Felipe de Moura Messias, Rodrigo Alvaro Brandão Lopes-Martins, Rodney Capp Pallotta, Jan Magnus Bjordal, Lúcio Frigo, Ernesto Cesar Pinto Leal Junior, Simone Teixeira, Rodrigo Labat Marcos, Luciano Ramos, Felipe de Moura Messias, Rodrigo Alvaro Brandão Lopes-Martins

Abstract

Arthritis of the knee is the most common type of joint inflammatory disorder and it is associated with pain and inflammation of the joint capsule. Few studies address the effects of the 810-nm laser in such conditions. Here we investigated the effects of low-level laser therapy (LLLT; infrared, 810-nm) in experimentally induced rat knee inflammation. Thirty male Wistar rats (230-250 g) were anesthetized and injected with carrageenan by an intra-articular route. After 6 and 12 h, all animals were killed by CO(2) inhalation and the articular cavity was washed for cellular and biochemical analysis. Articular tissue was carefully removed for real-time PCR analysis in order to evaluate COX-1 and COX-2 expression. LLLT was able to significantly inhibit the total number of leukocytes, as well as the myeloperoxidase activity with 1, 3, and 6 J (Joules) of energy. This result was corroborated by cell counting showing the reduction of polymorphonuclear cells at the inflammatory site. Vascular extravasation was significantly inhibited at the higher dose of energy of 10 J. Both COX-1 and 2 gene expression were significantly enhanced by laser irradiation while PGE(2) production was inhibited. Low-level laser therapy operating at 810 nm markedly reduced inflammatory signs of inflammation but increased COX-1 and 2 gene expression. Further studies are necessary to investigate the possible production of antiinflammatory mediators by COX enzymes induced by laser irradiation in knee inflammation.

Figures

Fig. 1
Fig. 1
Analysis of articular wash 3 and 6 h after induced inflammation. a Total number of leukocytes in articular lavage fluid after 3 h in the control group and after LLLT (n = 6 animals per group (*p < 0.05) (**p < 0.001). b Total number of leukocytes in articular lavage fluid after 6 h in the control group and after LLLT (n = 6 animals per group arthritis group (AT); the arthritis group treated with diclofenac (Diclof); the arthritis group treated with 1 J LLLT (AT + 1 J); the arthritis group treated with 3 J LLLT (AT + 3 J); the arthritis group treated with 6 J LLLT (AT + 6 J); the arthritis group treated with 10 J LLLT (AT + 10 J). Results are expressed as mean ( ± SEM)
Fig. 2
Fig. 2
a The number of neutrophils in the articular wash fluid 6 h after induced inflammation in the control group and after LLLT. b The number of mononuclear cells in the articular wash fluid 6 h after induced inflammation in the control group and after LLLT (n = 6 animals per group). Arthritis group (AT); arthritis group treated with diclofenac (Diclof); arthritis group treated with 1 J LLLT (AT + 1 J); arthritis group treated with 3 J LLLT (AT + 3 J); arthritis group treated with 6 J LLLT (AT + 6 J); arthritis group treated with 10 J LLLT (AT + 10 J). Results are expressed as mean ± SEM (**p < 0.001)
Fig. 3
Fig. 3
a The protein extravasation as an indicator of vascular permeability 6 h after induced inflammation. b The activity of myeloperoxidase 3 h after induced inflammation in the control and treated groups. c The activity of myeloperoxidase 6 h after induced inflammation in control and treated groups (* p < 0.05) (***p < 0.001). Arthritis group (AT); arthritis group treated with diclofenac (Diclof); arthritis group treated with 1 J LLLT (AT + 1 J); arthritis group treated with 3 J LLLT (AT + 3 J); arthritis group treated with 6 J LLLT (AT + 6 J); arthritis group treated with 10 J LLLT (AT + 10 J). Results are expressed as mean ± SEM
Fig. 4
Fig. 4
a The RNA expression of COX-1 enzyme measured by real-time PCR in joint cartilage. b The RNA expression of COX-2 enzyme measured by real-time PCR in joint cartilage (n = 6 animals per group (*p < 0.01). Arthritis group (AT); arthritis group treated with diclofenac (Diclof); arthritis group treated with 1 J LLLT (AT + 1 J); arthritis group treated with 3 J LLLT (AT + 3 J); arthritis group treated with 6 J LLLT (AT + 6 J); arthritis group treated with 10 J LLLT (AT + 10 J). Results are expressed as mean ± SEM
Fig. 5
Fig. 5
a The COX-1 RNA expression measured by real-time PCR at articular wash fluid. b The COX-2 RNA expression measured by real-time PCR at articular wash fluid (*p < 0.01) (n = 6 animals per group. Arthritis group (AT); arthritis group treated with diclofenac (Diclof); arthritis group treated with 1 J LLLT (AT + 1 J); arthritis group treated with 3 J LLLT (AT + 3 J); arthritis group treated with 6 J LLLT (AT + 6 J); arthritis group treated with 10 J LLLT (AT + 10 J). Results are expressed as mean ± SEM
Fig. 6
Fig. 6
a IL-1 levels at articular wash fluid measured by ELISA. b IL-6 levels at articular wash fluid measured by ELISA. c PGE2 levels at articular wash fluid measured by ELISA (*p < 0.05) (**p < 0.01) (***p < 0.001) (n = 6 animals per group). Arthritis group (AT); arthritis group treated with diclofenac (Diclof); arthritis group treated with 1 J LLLT (AT + 1 J); arthritis group treated with 3 J LLLT (AT + 3 J); arthritis group treated with 6 J LLLT (AT + 6 J); arthritis group treated with 10 J LLLT (AT + 10 J). Results are expressed as mean ± SEM

References

    1. Brandt KD, Dieppe P, Radin EL. Etiopathogenesis of Osteoarthritis. Rheum Dis Clin N Am. 2008;34:531–559. doi: 10.1016/j.rdc.2008.05.011.
    1. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci. 1999;4:D694–D703. doi: 10.2741/Martel.
    1. Towle CA, Hung HH, Bonassar LJ, et al. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthritis Cartilage. 1997;5:293–300. doi: 10.1016/S1063-4584(97)80008-8.
    1. Holt I, Cooper RG, Denton J, et al. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol. 1992;31:725–733. doi: 10.1093/rheumatology/31.11.725.
    1. Jikko A, Wakisaka T, Iwamoto M, et al. Effects of interleukin-6 on proliferation and proteoglycan metabolism in articular chondrocyte cultures. Cell Biol Int. 1998;22:615–621. doi: 10.1006/cbir.1998.0304.
    1. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 1996;39(9):1576–1587. doi: 10.1002/art.1780390919.
    1. Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol. 2002;55(5):300–304. doi: 10.1136/mp.55.5.300.
    1. Bensouyad A, Hollander AP, Dularay B, Bedwell AE, Cooper RA, Hutton CW, Dieppe PA, Elson CJ. Concentrations of glycosaminoglycans in synovial fluids and their relation with immunological and inflammatory mediators in rheumatoid arthritis. Ann Rheum Dis. 1990;49(5):301–307. doi: 10.1136/ard.49.5.301.
    1. Bjordal JM, Johnson MI, Lopes-Martins RA, Bogen B, Chow R, Ljunggren AE. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. BMC Musculoskelet Disord. 2007;22(8):51. doi: 10.1186/1471-2474-8-51.
    1. Chow RT, Barnsley L. Systematic review of the literature of low-level laser therapy (LLLT) in the management of neck pain. Lasers Surg Med. 2005;37(1):46–52. doi: 10.1002/lsm.20193.
    1. Chow RT, Johnson MI, Lopes-Martins RAB, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet. 2009;374(9705):1897–1908. doi: 10.1016/S0140-6736(09)61522-1.
    1. Bjordal JM, Johnson MI, Iversen V, Aimbire F, Lopes-Martins RA. Photoradiation in acute pain: a systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials. Photomed Laser Surg. 2006;24(2):158–168. doi: 10.1089/pho.2006.24.158.
    1. Aimbire F, Bjordal JM, Iversen VV, Albertini R, Frigo L, Pacheco MT, Castro-Faria-Neto HC, Chavantes MC, Labat RM, Lopes-Martins RA. Low-level laser therapy partially restores trachea muscle relaxation response in rats with tumor necrosis factor alpha-mediated smooth airway muscle dysfunction. Lasers Surg Med. 2006;38(8):773–778. doi: 10.1002/lsm.20357.
    1. Goupille P, Mulleman D, Chevalier X. Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience. Arthritis Res Ther. 2007;9(6):110. doi: 10.1186/ar2324.
    1. Haupt JL, Frisbie DD, McIlwraith CW, Robbins PD, Ghivizzani S, Evans CH, Nixon AJ. Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res. 2005;23(1):118–126. doi: 10.1016/j.orthres.2004.06.020.
    1. Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y. Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum. 1992;35(10):1197–1201. doi: 10.1002/art.1780351012.
    1. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232–234. doi: 10.1136/ard.52.3.232.
    1. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Sci World J. 2006;6:577–588. doi: 10.1100/tsw.2006.122.
    1. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6(12):1191–1197. doi: 10.1038/ni1276.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj